Pharmaceutical & Life Sciences News

Amarin Plunges After Vascepa Patents Are Invalidated (2)

March 30, 2020, 11:09 PM

Amarin Corp. plunged in after-hours trading after a U.S. judge invalidated its patents on the heart treatment Vascepa, opening the door to low-cost versions of a drug that accounts for almost all of its revenue.

Amarin pledged to appeal.

Six patents on the drug, which all expire in 2030, are invalid, said District Court Judge Miranda Du in Las Vegas. The judge’s decision was posted on the court’s electronic docket. Amarin, which closed at $13.58 in New York trading, fell more than 70% -- as low as $3.92 -- after the close of regular trading.

Vascepa, a synthetic version of...

To read the full article log in. To learn more about a subscription click here.